Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8137881rdf:typepubmed:Citationlld:pubmed
pubmed-article:8137881lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:8137881lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:8137881lifeskim:mentionsumls-concept:C0027061lld:lifeskim
pubmed-article:8137881lifeskim:mentionsumls-concept:C0002074lld:lifeskim
pubmed-article:8137881lifeskim:mentionsumls-concept:C0031441lld:lifeskim
pubmed-article:8137881lifeskim:mentionsumls-concept:C2004454lld:lifeskim
pubmed-article:8137881lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:8137881lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:8137881pubmed:issue1lld:pubmed
pubmed-article:8137881pubmed:dateCreated1994-4-25lld:pubmed
pubmed-article:8137881pubmed:abstractTextThe rate of recovery of rat myocardial alpha 1-adrenoceptor density and responsiveness after in vivo block with phenoxybenzamine (1 mg/kg, i.p.) have been investigated by measuring [3H]prazosin binding, and noradrenaline-stimulated [3H]inositol phosphate production. Repopulation of alpha 1-adrenoceptors was monoexponential, with a t1/2 of 33 h; functional recovery was also monoexponential, with t1/2 of 28 h. Furthermore, our results clearly demonstrate the absence of a receptor reserve for alpha 1-adrenoceptors mediating noradrenaline-stimulated phosphoinositide breakdown in rat myocardial tissue. These observations indicate a close relationship between the density of [3H]prazosin binding sites and the ability of alpha 1-adrenoceptors to respond to noradrenaline. Moreover, based on competition curves for inhibition of specific [3H]prazosin by WB-4101 to rat myocardial membranes 48 h and 7 days after the administration of phenoxybenzamine, the results suggest that rat myocardial membranes contain both alpha 1-adrenoceptors subtypes, i.e., alpha 1A and alpha 1B, in an approximate ratio of 20:80, and this relative ratio does not seem to be altered during the recovery process.lld:pubmed
pubmed-article:8137881pubmed:languageenglld:pubmed
pubmed-article:8137881pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8137881pubmed:citationSubsetIMlld:pubmed
pubmed-article:8137881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8137881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8137881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8137881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8137881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8137881pubmed:statusMEDLINElld:pubmed
pubmed-article:8137881pubmed:monthJanlld:pubmed
pubmed-article:8137881pubmed:issn0014-2999lld:pubmed
pubmed-article:8137881pubmed:authorpubmed-author:GascónSSlld:pubmed
pubmed-article:8137881pubmed:authorpubmed-author:BadiaAAlld:pubmed
pubmed-article:8137881pubmed:authorpubmed-author:SallésJJlld:pubmed
pubmed-article:8137881pubmed:authorpubmed-author:IvorraDDlld:pubmed
pubmed-article:8137881pubmed:issnTypePrintlld:pubmed
pubmed-article:8137881pubmed:day1lld:pubmed
pubmed-article:8137881pubmed:volume266lld:pubmed
pubmed-article:8137881pubmed:ownerNLMlld:pubmed
pubmed-article:8137881pubmed:authorsCompleteYlld:pubmed
pubmed-article:8137881pubmed:pagination35-42lld:pubmed
pubmed-article:8137881pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:meshHeadingpubmed-meshheading:8137881-...lld:pubmed
pubmed-article:8137881pubmed:year1994lld:pubmed
pubmed-article:8137881pubmed:articleTitleIn vivo recovery of alpha 1-adrenoceptors in rat myocardial tissue after alkylation with phenoxybenzamine.lld:pubmed
pubmed-article:8137881pubmed:affiliationDepartament de Farmacologia i Psiquiatria, Facultat de Medicina, Universitat Autònoma de Barcelona, Spain.lld:pubmed
pubmed-article:8137881pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8137881pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed